Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537314 · ClinicalTrials.gov registry record · Phase 1
Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02537314 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 27 participants.
The verdict
NCT02537314, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The overall hypothesis of this proposal is that nutrient sensing in the foregut regulates metabolic hormone secretion and nutrient metabolism via enteric neural signals, and these mechanisms might be defective in obesity.
Interventions
- OTHER placebo
- DRUG benzocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-09 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02537314
The ClinicalTrials.gov registry entry for NCT02537314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02537314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02537314 about?
NCT02537314 is a clinical study titled "Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans". The overall hypothesis of this proposal is that nutrient sensing in the foregut regulates metabolic hormone secretion and nutrient metabolism via enteric neural signals, and these mechanisms might be defective in obesity.
What is the current status of trial NCT02537314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-09. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT02537314?
The interventions under investigation include: placebo (OTHER), benzocaine (DRUG).
Who is sponsoring clinical trial NCT02537314?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.